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ABSTRACT
Objective: The main objective of this study was to investigate the release pattern of a poorly water-soluble drug quercetin (QU) by fabricating its 
cyclodextrin nanosponges.
Methods: Characterization of the original QU powder and QU-loaded nanosponges was carried out by the Fourier-transformed infrared (FTIR) 
spectroscopy, transmission electron microscopy (TEM), and dissolution tester. The drug release pattern was subjected to various kinetic models.
Results: FTIR studies confirmed the formation of inclusion complex of drug. The particle size analysis revealed that the average particle size 
measured by laser light scattering method is around 400–420 nm with low polydispersity index. The particle size distribution is unimodal and 
having a narrow range. A sufficiently high zeta potential indicates that the complexes would be stable and the tendency to agglomerate would be 
miniscule. TEM image revealed the porous nature of nanosponges. The dissolution of the QU nanosponges was significantly higher compared with 
the pure drug.
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INTRODUCTION
Flavonoids are a group of phenolic compounds that are widely 
distributed in different plant foods such as fruits, vegetables, leaves, 
and grains. There are different classes of flavonoids, for example, 
flavones, flavonones, isoflavones, flavonols, flavanonols, and 
anthocyanins [1,2]. Quercetin (QU) (3,3′,4′,5,7-pentahydroxyflavone) 
is an abundantly distributed plant; flavonol shows a wide range of 
pharmacological activities such as antioxidant, radical scavenging, 
and anticarcinogenic activity and is helpful in the recovery of 
n-diethyl nitrosamine-induced carcinogenesis [3,4], human leukemia 
cell [5], streptozotocin-induced diabetes [6], chronic renal failure, 
and reactive oxygen species-induced DNA damage [7]. QU and other 
flavonoids have been shown to modify eicosanoid biosynthesis, 
protect low-density lipoprotein from oxidation, prevent platelet 
aggregation, and promote relaxation of cardiovascular smooth muscle 
in antihypertensive and antiarrhythmic effects. In spite of this wide 
spectrum of pharmacological properties, its use in pharmaceutical 
field is limited by its low water solubility. QU is extremely hydrophobic 
in nature and has such poor absorption in the gastrointestinal tract. 
QU has a low solubility (7.7 μg/mL in water, 5.5 μg/mL in simulated 
gastric fluid, and 28.9 μg/mL in simulated intestinal fluid), which 
contributes to a low absorption in vivo. Its oral bioavailability is <17% 
in rats, even 1% in men [8-12]. As a result, the clinical application 
of the drug is greatly restricted. All these highlight the need for an 
improved formulation for QU with enhanced dissolution so that its 
absorption can be greatly enhanced. To overcome the above problems 
of QU and to achieve better clinical efficacy, many new drug delivery 
systems have been studied and developed in recent years, of which 
nanodrug delivery system has become a research hotspot with their 
numerous advantages such as reducing particle size, enhancing 
surface area, increasing drug permeability, improving intracorporeal 
circulation and distribution of the drug, and enhancing drug targeting 
and so on [13].
Cyclodextrins (CDs) are cyclic oligosaccharides joined to each other 
by α-(1→4)-linkages and synthesized by the enzymatic degradation 
of hydrolyzed starch. They consist of both hydrophilic inclusion 
complexes with functional groups on lipophilic compounds in 
aqueous solution [14]. The use of CDs represents another novel 
technological approach to increase drug solubility, stability, and oral 
bioavailability [15,16]. However, the inclusion constants of native CDs 
rarely exceed the value of 103. The cavity size of α-CD is insufficient 
for many drugs and γ-CD is expensive [17,18]. In general, β-CD has 
weaker complexing ability than conventional CDs. Among all CDs, 
β-CD is receiving attention due to its low cost and cavity size suitable 
for the widest range of drugs in aqueous media [19]. However, the 
low aqueous solubility and nephrotoxicity limited the use of β-CD, 
especially in parenteral drug delivery. Recently, CD-based nanosponges 
have emerged as a promising drug delivery platform for recalcitrant, 
difficult-to-formulate molecules [20-22].
Nanosponges are recently developed hypercross-linked CD polymers 
nanostructured to form three-dimensional networks; they are 
obtained by reacting CD with a suitable cross-linking agents. CD-based 
nanosponges showed superior complexing ability than natural CDs 
toward many molecules. They have been used to increase the solubility 
of poorly soluble actives, to protect the labile groups, and to control 
the release [23]. The present study was designed to investigate the 
feasibility of utilizing the CD-based nanosponges to improve the 
aqueous solubility and dissolution characteristics of QU.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i5.32864
Research Article
1Department  of   Vijaya  College  of  Pharmacy,  Hyderabad,  Telangana,  India.  2Department  of  Pharmaceutical  Technology,  Shri  Vishnu 
College of Pharmacy, Bhimavaram, Andhra Pradesh, India. 3Department of   Andhra University College of Pharmaceutical Sciences, 
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transport ; thus, it projected that delivered its active ingredient by coupled diffusion and erosion.
261
Asian J Pharm Clin Res, Vol 12, Issue 5, 2019, 260-264
 Sobitharani et al. 
MATERIALS AND METHODS
Materials
QU was purchased from Sigma-Aldrich, Singapore. CD nanosponges 
were prepared in our laboratory as reported elsewhere [24]. All other 
reagents used in the study were of reagent grade.
Methods
Preparation of QU-loaded nanosponges (QUNS)
Drug-loaded nanosponges were prepared by lyophilization technique as 
previously reported. Accurately weighed quantities of nanosponges were 
suspended in 50 mL of Milli-Q water using a magnetic stirrer, and then, the 
excess amount of QU was added and the mixture was sonicated for 10 min 
and was kept for 24 h under stirring. The suspensions were centrifuged 
at 2000 rpm for 10 min to separate the uncomplexed drug as a residue 
below the colloidal supernatant. The supernatant was lyophilized on a 
lyophilizer (LARK INDIA) at −20°C temperature and operating pressure 
13.33 mbar. The dried powder was stored in a desiccator [25].
Determination of QU loading in NS
Weighed amount of QUNS complexes was dissolved in methanol, 
sonicated for 10 min to break the complex, diluted suitably, and then 
analyzed by ultraviolet (UV) spectrophotometer at 372 nm.






Where, C is the concentration of QU measured in mg, M is the total particle 
mass – the yield of the formulation, T is the particle mass tested – weight 
of NS formulation used for quantification of QU, and W is the initial weight 
of the drug fed for loading – known amount of drug used for formulation.
Characterization of QU nanosponge complexes (QUNS)
The Fourier transformed infrared (FTIR) spectra of β-CD, plain 
nanosponges (NS2), QU, and QUNS complexes (QUNS2) were 
carried out by potassium bromide disk method using Tensor 27 
FTIR spectrophotometer (Bruker Optics, Germany) in the region of 
4000–600 cm−1. The particle size distribution was observed using a 
Mastersizer 2000 (Malvern Instruments Ltd., Worcestershire, UK) 
and the zeta potential of the same was determined using a Zetasizer 
(Malvern Instruments Ltd., Worcestershire, UK). The morphology of the 
QUNS was observed under transmission electron microscopy (TEM) 
(JEM-2000 EXII; JEOL, Tokyo, Japan).
Dissolution studies
The in vitro dissolution study of QU was carried out using multicompartment 
(n=6) rotating cells with a dialysis membrane (Sartorius cutoff 12,000 Da). 
The donor phase consisted of formulations containing 5 mg of QU in 
100 ml simulated gastric fluid (pH 6.4). The receptor phase also contains 
the same medium. The receptor phase was added with 0.5% w/v sodium 
lauryl sulfate (1 ml) to maintain proper sink conditions. The receptor phase 
was withdrawn completely after fixed time intervals, suitably diluted with 
distilled water and was analyzed using UV spectrophotometer at 372 nm. 
The experiment was carried out in triplicate.
Drug release kinetics
To elucidate the mode and mechanism of drug release, the data from the 
in vitro dissolution study were fitted into various mathematical models 
such as zero order, first order, Higuchi’s, and Korsmeyer-Peppas model. 
The release data from the nanosponge formulation were determined by 
curve fitting method. Data obtained from in vitro release studies were 
fitted to various kinetic equations.
Zero-order model:
  Qt = Q0+K0t (1)
Where, Qt is the amount of drug dissolved in time t, Q0 is the initial 
amount of drug in the solution, and K0 is the zero-order release constant.
First-order model:
  l n(Q∞–Qt)=lnQ0+Kt (2)
Where, Qt is the amount of drug dissolved in time t, Q0 is the initial 
amount of drug in the solution, Q∞ is the amount release in time ∞ 
(100% drug release), and K is the first-order release constant.
Higuchi model:
  Qt=kHt1/2 (3)
Where, Qt is the amount of drug dissolved in time t and kH is the Higuchi 
dissolution constant.








  logQt=logKk+nlogt (5)
Where, Qt is the amount of drug dissolved in time t, Q∞ is the amount 
release in time ∞, Kk is the rate constant, and n is the diffusional 
exponent, this indicates the drug release mechanism.
RESULTS AND DISCUSSION
Three types of β-CD nanosponges prepared by varying the 
cross-linking density were used in this study. QU was loaded into three 
types of nanosponges by lyophilization method. The drug loading was 
Table 1: Percent drug loading in nanosponges




All determinations were performed in triplicate and values were expressed as 
mean±SD, n=3. SD: Standard deviation, QUNS: Quercetin-loaded nanosponges
Fig. 1: Fourier transformed infrared spectra of β-cyclodextrin, 
plain nanosponges (NS2), quercetin (QU), and QUNS2
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determined for the estimation of drug association with nanosponges, 
i.e., the amount of drug encapsulated into nanosponges, calculated by 
analyzing a fixed amount of formulation. Percent drug loading into 
all the three types of nanosponges (QUNS1-QUNS3) is presented in 
Table 1.
Among all the three types of nanosponges (NS1-NS3), the loading 
efficiency was found to be higher in NS2 (1:4 β-CD: DPC) as much as 
39% w/w, while 16% and 29% w/w in NS1 and NS3 nanosponges, 
respectively. Due to the better solubilization and loading capacities, 
QUNS2 was selected for further studies.
FTIR spectroscopy
Fig. 1 shows a comparison of FTIR spectra of β-CD, NS2, QU, and 
QUNS2. NS2 showed a characteristic peak of carbonate bond at 
around 1720–1750 cm−1 which confirms the formation of CD-based 
nanosponges. In addition, the other characteristics peak of NS was 
found at 2918 cm−1 due to the C–H stretching vibration, 1418 cm−1 
due to C–H bending vibration, and 1026 cm−1 due to C–O stretching 
vibration of primary alcohol. FTIR studies showed that there are weak 
interactions between NS and QU that were evident from broadenings and 
disappearance of the drug peaks in case of complexes. The comparison 
of FTIR spectra of QU and complex showed that there is a major change 
in the fingerprint region, i.e., 900–1400 cm−1. The main characteristic 
peaks of QU are at around 1663, 1608, 1383, 1318, 1265, 1203, 1167, 
and 820–940 cm−1. These QU characteristic peaks were broadened or 
shifted in the formulations suggesting definite interactions between 
QU and NS. FTIR spectroscopy confirmed the formation of inclusion 
complex of QU with nanosponges.
Particle size, polydispersity index, and zeta potential determination
The particle size analysis of NS2 and QUNS2 suspensions revealed 
that the average particle size measured by laser light scattering 
method is around 400–420 nm with low polydispersity index. The 
particle size distribution is unimodal and having a narrow range as 
seen in Table 2. A sufficiently high zeta potential indicates that the 
complexes would be stable and the tendency to agglomerate would 
be miniscule. A narrow PI means that the colloidal suspensions are 
homogenous in nature.
Fig. 4: Plot of zero-order release kinetics of the quercetin-loaded 
nanosponges formulation








NS2 408±18 0.18±0.005 −19.34±1.8
QUNS2 413±27 0.25±0.005 −20.55±1.4
All determinations were performed in triplicate and values were expressed as 
mean±SD, n=3. SD: Standard deviation, QUNS: Quercetin-loaded nanosponges
Fig. 2: Transmission electron microscopy images of plain 
nanosponge and quercetin-loaded nanosponges
Fig. 3: Dissolution profile of original quercetin and quercetin-
loaded nanosponges
Fig. 5: Plot of first-order release kinetics of the quercetin-loaded 
nanosponges formulation
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TEM
TEM studies showed that the regular spherical shape and size of both 
the nanosponges that are unaffected even after drug encapsulation. TEM 
measurement revealed the porous structure of nanosponges as shown 
in Fig. 2. TEM studies revealed the porous structure of nanosponges and 
size of NS that are unaffected even after drug encapsulation (Table 3).
In vitro release of QU from nanosponge formulations
The dissolution profiles of plain QU and QUNS2 complex in simulated 
gastric medium are shown in Fig. 3. The in vitro release experiments 
showed a rapid and complete release of QU from nanosponges. From 
in vitro release, it was found that the complex showed a significant 
improvement in the rate of release as compared with the pure drug. 
The dissolution of pure QU is not even 2% in 120 min, whereas the 
drug encapsulated in nanosponges showed faster release. An average 
45–55% QU was released within 30 min showing rapid burst release. 
This was normally attributed to the fraction of QU which was adsorbed 
or encapsulated as non-inclusion complex on the NS surface. On the 
addition of the formulation to the release medium, this fraction of QU 
was diffused rapidly into the surrounding liquid. The maximum release 
of QU after 120 min from QUNS2 was 91.54%. After the initial effect, 
the release rate was found to be slower from the complex. The slower 
and sustained release of QU can be attributed to diffusion of the QU 
entrapped within the nanosponges as inclusion complex.
Release kinetics
Drug release data for the nanosponge formulation were fitted into 
various kinetic equations to find out the order and mechanism of drug 
release. The various release kinetic curves are shown in Fig. 4-7. The 
correlation coefficient showed that the release profile followed the 
Korsmeyer-Peppas model (R2=0.976), the release exponent, n was found 
to be 0.9911 indicating non-Fickian (anomalous) transport. Kinetic 
analysis of drug release profiles showed that the systems predominantly 
released nimodipine in a non-Fickian (anomalous) with a strong 
correlation coefficient (R2=0.94572) of Korsmeyer-Peppas model.
CONCLUSION
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Table 3: Release kinetics of optimized formulation of quercetin nanosponge complex
Formulation code Zero order First order Higuchi Korsmeyer-Peppas
R2 n R2 n R2 n R2 n
QUNS 0.47925 0.22377 0.84504 0.0045 0.76092 5.41628 0.976 0.9911
QUNS: Quercetin-loaded nanosponges
Fig 7: Plot of Korsmeyer-Peppas release kinetics of the quercetin-
loaded nanosponges formulation
Fig. 6: Plot of Higuchi release kinetics of the quercetin-loaded 
nanosponges formulation
From  the  above  results,  it  is  apparent  that  the  regression 
coefficient  value  closer  to  unity  in  case  of  Korsmeyer-Peppas  model 
indicates that the drug release exponentially to the elapsed time. The 
data indicate a more linearity when plotted by the first-order equation. 
Hence,  it  can  be  concluded  that  the  major  mechanism  of  drug  release 
follows first-order kinetics.  Further,  the translation of the data from the 
dissolution  studies  suggested  possibility  of  understanding  the 
mechanism of drug release by configuring the data into various 
mathematical modelings such as Higuchi and Korsmeyer-Peppas 
plots. Further, n value obtained from the Korsmeyer-Peppas plots, 
i.e., 0.9911 indicating non-Fickian (anomalous) transport ; thus, it 
projected  that  delivered  its  active  ingredient  by  coupled  diffusion 
and erosion.
CD nanosponges have attracted the attention of many scientists 
due  to  their  enhancing  solubility  of  poorly  water-soluble 
drugs.  They can incorporate a wide range of hydrophilic 
and  lipophilic  drug  molecules  and  they  have  the  ability  to  form 
inclusion  and  non-inclusion  complexes.  The  higher  solubilization 
potential  of  nanosponges  can  be  attributed  to  the  formation  of 
inclusion  complex  with  drug  as  well  as  entrapment  in  the  matrix 
form. From  in vitro  release, it was found that the complex showed a 
significant  improvement  in  the  rate  of  release  as  compared  with 
the  pure  drug.  Further,  the  translation  of  the  data  from  the 
dissolution  studies  suggested  possibility  of  understanding  the 
mechanism of drug release by configuring the data into various 
mathematical modelings such as Higuchi and Korsmeyer-Peppas plots. 
Further, n value obtained from the Korsmeyer-Peppas plots, i.e., 0.9911 
indicating non-Fickian (anomalous) transport ; thus, it projected that 
delivered its active ingredient by coupled diffusion and erosion.
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